Crinetics Pharmaceuticals (NASDAQ: CRNX) announced it has randomized the first patient in its pivotal Phase 3 CAREFNDR trial evaluating paltusotine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE